Pharmacists’ Perspective on Managing Multiple Myeloma: FAQs

1:08 - Take-home thoughts for R/R MM 
3:47 - Summary of BCMA-targeted CAR T-cell therapy; Use of novel agents for R/R MM
6:47 - Information on melphalan flufenamide; Combination approaches with selinexor in clinical practice
9:59 - Cost considerations for treatment options in R/R MM
12:25 - Administration considerations for subcutaneous daratumumab and venetoclax in R/R MM

Faculty

Kathryn Maples, PharmD, BCOP
Clinical Pharmacy Specialist, Multiple Myeloma
Winship Cancer Institute, Emory Healthcare
Atlanta, Georgia

Tim Peterson, PharmD, BCOP
Clinical Pharmacy Specialist – Multiple Myeloma
Memorial Sloan Kettering Cancer Center
New York, New York
 

Content based on a CE activity supported by educational grants from Karyopharm Therapeutics, Inc. and Oncopeptides, Inc.

Link to full activity: 
https://www.proce.com/RRMM